Molecular insights into domestic cat hepatitis B virus linking genome to function Authors: Sofija Šolaja, Vesna Milićević, Dimitrije Glišić, Andrea Radalj, Miloš Đurić, Aleksandra Knežević, Jakov Nišavić Published: 2026 ABSTRACT Domestic cat hepatitis B virus (DCHBV) is a member of the Hepadnaviridae family and has been associated with hepatocellular carcinoma (HCC) in cats. This study aimed to determine the prevalence of DCHBV and associations with feline immunodeficiency virus (FIV), feline leukaemia virus (FeLV) and feline coronavirus (FCoV) infections in cats in Serbia, and to characterise the detected DCHBV genomes. Whole blood, serum and liver samples from 308 animals were screened by real-time (RT-)PCR for DCHBV, FIV, FeLV, and FCoV. The prevalence of DCHBV was 2.60%, with no significant associations observed between DCHBV infection and age, sex, or coinfection status. Three whole genome sequences were obtained, and phylogenetic analysis demonstrated that the Serbian strains belong to genotype A. Molecular analysis revealed three unique nonsynonymous substitutions in the S ORF. Within the C ORF, a 28–amino acid N-terminal precore region with conserved cysteine residues critical for protein maturation was identified, along with the C-terminal arginine-rich domain. A putative core promoter region was detected, containing two motifs analogous to the pgRNA and pcRNA initiator elements described in hepatitis B virus (HBV). DCHBV sequences contained two 11-bp direct repeats with DR2 located in X ORF and DR1 positioned in the C ORF. This study represents the first report of DCHBV in Serbia, providing new insights into its epidemiology and genomic features. The findings expand current knowledge of its molecular diversity and underscore the importance of genomic characterisation for understanding its role in liver disease development.Supplementary InformationThe online version contains supplementary material available at 10.1007/s11259-026-11236-x. Introduction Domestic cat hepatitis B virus (DCHBV), also referred to as Orthohepadnavirus felis domestici, is a recently identified member of the genus Orthohepadnavirus within the family Hepadnaviridae (Magnius et al. 2020). It was first detected in a domestic cat diagnosed with lymphoma in Australia in 2018 (Aghazadeh et al. 2018). Since then, DCHBV has been reported in domestic cats, wild felids, and dogs, and has been detected across multiple continents, including Australia, Asia, Europe, South and North America (Fruci et al. 2023; Diakoudi et al. 2025; de Oliveira-Filho et al. 2025). In Europe, DCHBV has been detected in countries such as Italy, Germany, France, Croatia, the United Kingdom and Bulgaria (de Oliveira-Filho et al. 2025). Recent molecular epidemiological studies suggest the existence of two distinct genotypes of DCHBV: genotype A, which has been identified in Europe, Asia, and North America, and genotype B, which appears to be mainly restricted to Japan, the USA, and Brazil (de Oliveira-Filho et al. 2025; Cavasin et al. 2025). Members of the Hepadnaviridae family are characterised by small, enveloped virions containing a circular, partially double-stranded DNA genome. The prototype member, hepatitis B virus (HBV), is approximately 3.2 kbp long and contains four overlapping open reading frames (ORFs). The P ORF is the longest and encodes for viral polymerase, which acts as DNA polymerase, reverse transcriptase and RNase (Quarleri 2014). The preS/S ORF comprises the preS1, preS2 and S regions, which encode the large (L), middle (M), and small (S) envelope proteins, known as hepatitis B surface antigen (HBsAg). The preS1 promoter regulates the transcription of preS1 mRNA, while the S promoter regulates the transcription of preS2/S mRNA. The preC/C ORF has two initiation codons and encodes the capsid core protein (HBc) and the precore protein, which is further processed to produce hepatitis B e antigen (HBeAg) (Chuang et al. 2022). The X ORF encodes the HBx protein, which plays a key role in the development of hepatocellular carcinoma (HCC) (Quarleri 2014). The core promoter (CP) regulates the transcription of precore RNA (pcRNA) and pregenomic RNA (pgRNA), with the latter serving both as the mRNA for the core protein and polymerase and as the template for reverse transcription during genome replication (Chuang et al. 2022). Similar to HBV, the DCHBV genome has been described as approximately 3.2 kb in length with four partially overlapping ORFs (P, S, C and X) (Aghazadeh et al. 2018). However, the functional organisation of the genome has not yet been fully described. DCHBV has been detected in cats presenting with hepatic disorders, including HCC and chronic hepatitis (Pesavento et al. 2019; Capozza et al. 2023b; Piewbang et al. 2023; Cavasin et al. 2025). Although its role in disease pathogenesis remains under investigation, it is of particular interest due to its genetic and functional similarities with HBV, which in humans is a well-established cause of acute and chronic hepatitis, hepatic fibrosis, and HCC (Cavasin et al. 2025). In humans, coinfection with human immunodeficiency virus (HIV) and HBV is associated with more rapid disease progression and an accelerated onset of AIDS (Kenfack-Momo et al. 2022). Analogously, several studies have explored potential associations between DCHBV and feline retroviruses, specifically feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV) (Lanave et al. 2019; Piewbang et al. 2020; Capozza et al. 2023a). However, the relationship between DCHBV infection and FeLV or FIV status in cats remains inconclusive. Feline infectious peritonitis (FIP) is caused by feline coronavirus (FCoV) following mutations in the viral genome within the infected host. Co-infection with FCoV and other viruses is relatively common in animals exhibiting clinical signs of FIP, with retroviral coinfections often acting as a predisposing factor for disease development (Oguzoglu et al. 2021; Moyadee et al. 2023). This study aimed to investigate, for the first time, the presence of DCHBV in the domestic cat population in Serbia and to explore potential associations with coinfections caused by other viruses. Although parallels between DCHBV and HBV have been widely discussed, most have focused primarily on detection and genomic comparisons of DCHBV, while the detailed genomic organisation and the protein analysis remain poorly characterised. To address this knowledge gap, whole-genome sequencing and phylogenetic analysis were performed, alongside detailed amino acid analysis and assessment of putative functional genomic regions. This integrated approach was undertaken to improve understanding of DCHBV genomic structure, protein features, and overall genetic diversity. Materials and methods Sample collection Whole blood and serum samples were collected after routine diagnostic investigations from cats presented to private and university veterinary clinics from April 2024 until May 2025, using a convenience sampling approach. Liver samples were obtained post-mortem from cats submitted for necropsy at the Department of Forensic Pathology, Faculty of Veterinary Medicine, University of Belgrade. The samples were stored at -20 °C until they were transported to the Institute of Veterinary Medicine of Serbia for sample preparation. Data on the animal’s age and sex were retrieved from clinical records and necropsy documentation. Sample preparation and extraction of nucleic acids Liver samples were cut into 1 cm³ pieces, homogenised using a sterile mortar and pestle, and subsequently diluted 1:10 in phosphate-buffered saline (PBS, pH 7.2). The homogenates were centrifuged at 1,500 × g for 10 min. The supernatant was decanted and stored at -80 °C until further processing. Viral nucleic acids were extracted from 200 µL of the resulting supernatant, as well as from whole blood and serum, using the IndiMag Pathogen Kit (Indical Bioscience GmbH, Leipzig, Germany) following the manufacturer’s instructions. Molecular detection of DCHBV, FeLV, FIV and FCoV Detection of DCHBV, FeLV, FIV, and FCoV was performed on all samples using specific primer and probe sets (Table 1). Detection of DCHBV, FeLV, and FIV was performed using a 20 µL reaction mixture prepared with the Luna Universal Probe qPCR Master Mix (New England BioLabs, Ipswich, MA, USA). Each reaction contained 10 µL of Master Mix, 0.8 µL of 10 µM forward primer, 0.8 µL of 10 µM reverse primer, 0.4 µL of 10 µM probe, 5 µL of DNA template, and nuclease-free water to bring the final volume to 20 µL. The thermal cycling conditions included an initial denaturation at 95 °C for 1 min, followed by 50 cycles of 95 °C for 10 s and 60 °C for 30 s. For the detection of FCoV, a 20 µL one-step RT-qPCR reaction was prepared using the Luna Universal Probe One-Step RT-qPCR Kit (New England BioLabs, Ipswich, MA, USA). The reaction mixture consisted of 10 µL of Luna Universal One-Step Reaction Mix (2X), 1 µL of Luna WarmStart® RT Enzyme Mix (20X), 0.8 µL of 10 µM forward primer, 0.8 µL of 10 µM reverse primer, 0.4 µL of 10 µM probe, 5 µL of RNA template, and nuclease-free water to complete the volume. Thermal cycling was performed according to the manufacturer’s instructions: reverse transcription at 55 °C for 10 min, initial denaturation at 95 °C for 1 min, followed by 50 amplification cycles of 95 °C for 10 s and 60 °C for 30 s. All real-time PCR reactions were performed using the QIAquant 96 system (QIAGEN, Venlo, Netherlands). Each run included a positive, a negative and a non-template control (NTC). A synthetic positive control corresponding to a 1,235-bp fragment of the P ORF of the DCHBV reference strain (NC_040719), encompassing the primer and probe target region described by Lanave et al. 2019; was synthesised (Macrogen Europe, Amsterdam, Netherlands) and used in real-time PCR assays. Previously confirmed positive samples were used as positive controls for the detection of FIV, FeLV, and FCoV. The internal positive RNA control (VetMax™ Xeno™ Internal Positive Control RNA; Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) and DNA control (VetMax™ Xeno™ Internal Positive Control DNA; Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) were added to the samples to monitor the extraction and amplification processes. Table 1Primers and probes used for the detection of FIV, FeLV, FCoV and DCHBVVirusPrimersSequence 5’-3’ReferenceFIVFIV-B FAGACCGCTGCCCTATTTCACT(Leal et al. 2015)FIV-B RTTCTGGCTGGTGCAAATCTGFIV-B Probe[FAM]TGCCTGTTGTTCTTGAGTTAATCCTATTCCCA[TAMRA]FeLVFeLV-U3 FAACAGCAGAAGTTTCAAGGCC(Cattori Valentino and Hofmann-Lehmann 2008)FeLV-U3 RTTATAGCAGAAAGCGCGCGFeLV-U3 Probe[FAM]CCAGCAGTCTCCAGGCTCCCCA[TAMRA]FCoVFCoV FGATTTGATTTGGCAATGCTAGATTT(Kobialka et al. 2021)FCoV RAACAATCACTAGATCCAGACGTTAGCTFCoV Probe[FAM]TCCGCTATGACGAGCCAACAATGGA[TAMRA]DCHBVDCH FGTGCTCTGATAACCGTATGCTC(Lanave et al. 2019)DCH RTCCATATAAGCAAACACCATACAATDCH Probe[FAM]TCCTCCTAACCATTGAAGCCAGACTACT[TAMRA] Table 1Primers and probes used for the detection of FIV, FeLV, FCoV and DCHBVVirusPrimersSequence 5’-3’ReferenceFIVFIV-B FAGACCGCTGCCCTATTTCACT(Leal et al. 2015)FIV-B RTTCTGGCTGGTGCAAATCTGFIV-B Probe[FAM]TGCCTGTTGTTCTTGAGTTAATCCTATTCCCA[TAMRA]FeLVFeLV-U3 FAACAGCAGAAGTTTCAAGGCC(Cattori Valentino and Hofmann-Lehmann 2008)FeLV-U3 RTTATAGCAGAAAGCGCGCGFeLV-U3 Probe[FAM]CCAGCAGTCTCCAGGCTCCCCA[TAMRA]FCoVFCoV FGATTTGATTTGGCAATGCTAGATTT(Kobialka et al. 2021)FCoV RAACAATCACTAGATCCAGACGTTAGCTFCoV Probe[FAM]TCCGCTATGACGAGCCAACAATGGA[TAMRA]DCHBVDCH FGTGCTCTGATAACCGTATGCTC(Lanave et al. 2019)DCH RTCCATATAAGCAAACACCATACAATDCH Probe[FAM]TCCTCCTAACCATTGAAGCCAGACTACT[TAMRA] Primers and probes used for the detection of FIV, FeLV, FCoV and DCHBV DCHBV whole genome sequencing DCHBV-positive samples with Ct < 30 were selected for targeted whole genome Sanger sequencing. Amplification of the complete genome was performed using five primer sets (Table 2) targeting overlapping regions of the viral genome (Aghazadeh et al. 2018). Modifications to the protocol were applied through adjustments of the annealing temperatures to optimise amplification. PCR reactions were prepared using Maxima Hot Start PCR Master Mix (2X) (Thermo Scientific, Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. Primer concentrations were 0.4 µM for the sets Cir8F/Cir7R, Cir7F/Cir5R, and Cir7F/Cir1R, and 0.3 µM for Cir5F/Cir4R and HgapF/HgapR. Each reaction contained 5 µL of DNA template, with nuclease-free water added to a final volume of 50 µL. Thermal cycling conditions consisted of initial denaturation at 95 °C for 15 min, followed by 45 cycles of denaturation at 95 °C for 30 s, annealing for 1 min at primer-specific temperatures (57 °C for Cir5F/Cir4R, 58 °C for Cir8F/Cir7R, and 55 °C for Cir7F/Cir5R, Cir7F/Cir1R, and HgapF/HgapR), extension at 72 °C for 1 min, and a final extension at 72 °C for 10 min. PCR products were analysed by electrophoresis on a 1.5% agarose gel and visualised under UV illumination. Amplicons of the expected size were bidirectionally Sanger sequenced (Macrogen Europe, Amsterdam, Netherlands). Table 2Primers used for whole genome amplification of DCHBVPrimersSequence 5’-3’Size (bp)ReferenceCir 5 FTTGGCACCTGGATTCGCA1400Cir 4RAGATGTTCCACACTCTTAGCCCir 8 FTTGGCACCTGGATTCGCA900Cir 7RCGTAGACGAAGGACACGTCCir 7 FCCATCGATTTACACACTTCCCA950Aghazadeh et al. 2018Cir 5RTGCGAATCCAGGTGCCAACir 7 FCCATCGATTTACACACTTCCCA1000Cir 1RATAACCGTATGCTCCGGAAGHgap FGTGCTCTGATAACCGTATGCTC230Hgap RCTAGAATGGCTACATGGGGTTAG Table 2Primers used for whole genome amplification of DCHBVPrimersSequence 5’-3’Size (bp)ReferenceCir 5 FTTGGCACCTGGATTCGCA1400Cir 4RAGATGTTCCACACTCTTAGCCCir 8 FTTGGCACCTGGATTCGCA900Cir 7RCGTAGACGAAGGACACGTCCir 7 FCCATCGATTTACACACTTCCCA950Aghazadeh et al. 2018Cir 5RTGCGAATCCAGGTGCCAACir 7 FCCATCGATTTACACACTTCCCA1000Cir 1RATAACCGTATGCTCCGGAAGHgap FGTGCTCTGATAACCGTATGCTC230Hgap RCTAGAATGGCTACATGGGGTTAG Primers used for whole genome amplification of DCHBV Sequence analysis Sequence analyses were conducted in Geneious Prime v2025.1.2 (Dotmatics, Boston, MA, USA). Amplicon sequences were aligned using the de novo assembly algorithm, and consensus sequences were generated to reconstruct complete genomes. High-quality whole genome sequences were submitted to the NCBI GenBank database. The obtained sequences were subsequently aligned with 85 publicly available full-length DCHBV genomes using the MAFFT algorithm (Supplementary material 1). In the sequence analysis, reference DCHBV (NC_040719) and HBV (NC_003977) sequences were used for genome annotation and characterisation. Phylogenetic reconstruction was performed on the IQ-TREE web server employing the maximum likelihood (ML) method, with branch support assessed by 1,000 ultrafast bootstrap replicates and SH-aLRT tests (Trifinopoulos et al. 2016). The resulting ML phylogenetic tree was visualised in FigTree v1.4.4. Amino acid sequence analysis of surface proteins, pre-core, and core proteins was performed in Geneious Prime v2025.1.2 (Dotmatics, Boston, MA, USA). Statistical analysis The statistical analysis was performed using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). The overall prevalence of viral infections, as well as the prevalence by sex, was calculated with 95% confidence intervals using the Wilson method. Associations between infection status and categorical variables such as sex and age were assessed using a chi-square test when all expected cell counts were ≥ 5. When this assumption was not met, Fisher’s exact test was applied. A predefined level of statistical significance (α) was set at 0.05. In addition, Fisher’s exact test was applied to examine the relationship between DCHBV infection and coinfection with retroviruses or FCoV. Results In this study, samples from 308 domestic cats were analysed, including 141 males and 167 females. Out of the 308 animals, 34 were categorised as juvenile (< 12 months) and 274 as adults (≥ 12 months). A total of 253 whole blood samples, 74 serum samples from veterinary clinics, and 27 liver samples, obtained after necropsy, were tested. Paired whole blood and serum samples were obtained from 45 cats, while only whole blood was available from 207 and only serum from 28 animals (Supplementary Material 2). In the total sample set, DCHBV was detected in 8 cats, FIV in 11, FeLV in 18, and FCoV in 13, corresponding to prevalence rates of 2.60%, 3.57%, 5.84%, and 4.22%, respectively (Table 3). The majority of infected animals were adults, whereas only a single juvenile cat tested positive exclusively for DCHBV, with no evidence of coinfection or other viral agents in this age group. Coinfections with FIV and FeLV were detected in two DCHBV-positive cats, whereas the remaining six were infected with DCHBV alone. No coinfection with more than one additional virus was observed, and no coinfections with FCoV were detected. Table 3Prevalence of FIV, FeLV, FCoV, and DCHBV in domestic cats by sex, with 95% confidence intervalsSample sizeFIV+FeLV+FCoV+DCHBV+ n %95% CI n %95% CI n %95% CI n %95% CIin total308113.572.01–6.28185.843.73–9.05134.222.48–7.0982.61.32–5.04male14153.551.52–8.385.672.9–10.864.261.96–8.9710.710.13–3.91female16763.591.66–7.62105.993.28–10.6774.192.05–8.474.192.05–8.4 Table 3Prevalence of FIV, FeLV, FCoV, and DCHBV in domestic cats by sex, with 95% confidence intervalsSample sizeFIV+FeLV+FCoV+DCHBV+ n %95% CI n %95% CI n %95% CI n %95% CIin total308113.572.01–6.28185.843.73–9.05134.222.48–7.0982.61.32–5.04male14153.551.52–8.385.672.9–10.864.261.96–8.9710.710.13–3.91female16763.591.66–7.62105.993.28–10.6774.192.05–8.474.192.05–8.4 Prevalence of FIV, FeLV, FCoV, and DCHBV in domestic cats by sex, with 95% confidence intervals DCHBV was detected in one liver sample from a cat submitted for necropsy and in two cats for which only whole blood samples were available. Among the five DCHBV-positive animals from which both serum and whole blood samples were collected, two tested positive in both sample types, whereas three were positive only in serum (Supplementary material 2). Statistical analysis revealed no significant difference in viral prevalence, although seven of the eight DCHBV-positive cats were female. No significant difference in prevalence was observed between age categories. Additionally, Fisher’s exact test showed no statistically significant associations (p > 0.05) between DCHBV infection and coinfection with other viruses. DCHBV whole genome sequencing and phylogenetic analysis Whole blood and serum samples with Ct values < 30 from five animals were selected for whole genome sequencing. Complete genome sequences were successfully obtained from three animals, whereas samples from the remaining two yielded low-quality data, and full genomes could not be recovered. Of the three complete genomes, one was obtained from a cat for which only whole blood was available, while the other two were recovered from both serum and whole blood samples. The sequences were annotated and submitted to the NCBI GenBank database under the accession numbers PX147448, PX147449, and PX147450. The sequences were 3184 bp in length, with P ORF 2514 bp, S ORF 1146 bp, C ORF 657 bp, and X ORF 438 bp. All three sequences contained the 3-bp deletion at positions 2962–2964 compared to the reference sequence (NC_040719). Phylogenetic analysis revealed that the obtained sequences clustered within genotype A. The sequences generated in this study showed the highest similarity to strains reported in Taiwan (2023), France (2022), and the United Kingdom (2018) (Fig. 1, Supplementary Material 5). In contrast, sequences from neighbouring countries clustered differently, with Croatian strains grouping with those from Germany and Bulgarian strains clustering with Italian strains (Fig. 1, Supplementary Material 5). Fig. 1Maximum likelihood phylogenetic tree constructed using 85 publicly available sequences and three sequences obtained in this study. The tree is midpoint-rooted, with branches corresponding to genotype B shown in blue, while genotype A branches are shown in black. Sequences generated in this study are highlighted in red. Black circles at nodes indicate strong support (SH-aLRT ≥ 80% and UFboot ≥ 95%) Maximum likelihood phylogenetic tree constructed using 85 publicly available sequences and three sequences obtained in this study. The tree is midpoint-rooted, with branches corresponding to genotype B shown in blue, while genotype A branches are shown in black. Sequences generated in this study are highlighted in red. Black circles at nodes indicate strong support (SH-aLRT ≥ 80% and UFboot ≥ 95%) Protein analysis The S ORF of all three sequences was 1,146 bp, encoding 382 amino acids. A 3-bp deletion/insertion was consistently observed in all three sequences in the PreS1 region at amino acid position 82. Several unique amino acid substitutions at previously unreported positions were identified in the Serbian strains (Supplementary material 3). The sequences DCHBV_SRB_154_PX147448_Serbia_2025 and DCHBV_SRB_313_PX147449 each carried substitutions at unique positions compared to all other available sequences, L242R and T70P, respectively. Additionally, DCHBV_SRB_313_PX147449 exhibited an I204N substitution that was not detected in any other sequence in the dataset, although other amino acid substitutions have been detected at this position. This strain also exhibited an I274F substitution resulting from two nucleotide changes (A355T and T357C). Three nonsynonymous substitutions (Q77H, G89D in the PreS1 region, and T271A in the S region) were present in all three sequences and were also present in multiple other strains in the alignment. The sequence DCHBV_SRB_73_PX147450 carried a V99I substitution, which was present in other sequences as well. Amino acid sequence analysis revealed that the 9-NPLGFFP-15 NTCP binding domain is conserved in all DCHBV sequences (Supplementary material 4). The C ORF of all three sequences from Serbia was 657 bp in length, with all observed mutations being synonymous. A region homologous to the HBV N-terminal precore sequence was identified in DCHBV sequences between nucleotide positions 1665–1748, corresponding to 28 amino acids (Fig. 2, Supplementary Material 6). Compared with the HBV N-terminal precore sequence, DCHBV contains a 3-bp deletion, resulting in the loss of serine at position − 19. This region appears highly conserved among DCHBV sequences, with mutations detected only at nucleotide positions 1689 and 1715. Cysteine residues were identified in the precore sequence at positions − 7, −18, and − 22. An arginine-rich domain (ARD) was identified at the C-terminal end of the core protein (Fig. 2, Supplementary Material 6) and comprised three typical arginine clusters. Upstream of these clusters, two atypical clusters were also observed. One, which is absent in HBV and contains only two arginine residues, and one in which an alanine residue is positioned between two arginines. Fig. 2Schematic representation of genomic and protein features of the DCHBV core region. (a) Organisation of the putative core promoter and precore sequence, with the positions of direct repeats (DR1 and DR2) and key regulatory motifs indicated. (b) Structural organisation of the precore/core protein, showing the N-terminal precore peptide and the C-terminal ARD. Amino acid sequence differences in the alignment of the precore sequence and the ARD from the Serbian DCHBV strain (DCHBV_SRB_73) and the HBV reference sequence (NC_003977) are highlighted in red. The coordinates correspond to HBV reference genome numbering Schematic representation of genomic and protein features of the DCHBV core region. (a) Organisation of the putative core promoter and precore sequence, with the positions of direct repeats (DR1 and DR2) and key regulatory motifs indicated. (b) Structural organisation of the precore/core protein, showing the N-terminal precore peptide and the C-terminal ARD. Amino acid sequence differences in the alignment of the precore sequence and the ARD from the Serbian DCHBV strain (DCHBV_SRB_73) and the HBV reference sequence (NC_003977) are highlighted in red. The coordinates correspond to HBV reference genome numbering Regulatory regions A putative CP of approximately 235 bp in length was identified, overlapping with the P, X and C ORFs. Within this region, the potential basic core promoter (BCP) contained multiple TATA box-like motifs. In the BCP, a putative regulatory sequence, 5′-CATAAAAC-3′ (nucleotides 1640–1647), was identified in DCHBV and found to be well conserved. Additionally, the sequence 5′-CATCT-3′ (nucleotides 1668–1672) was detected at the beginning of the C ORF in DCHBV and may also possess a regulatory function. Although several TATA-like sequences were identified upstream of the PreS1 region, none matched the TATA box described in HBV. Two 11-bp direct repeats (DR1 and DR2) with the conserved motif 5′-TTCACCTGTGC-3′ were identified in DCHBV sequences. DR2 was located in the X ORF (nucleotides 1442–1452), whereas DR1 was positioned in the C ORF (nucleotides 1675–1685) (Fig. 2, Supplementary Material 7). Compared with HBV, which contains the repeat 5′-TTCACCTCTGC-3′, the DCHBV motif differed by a single nucleotide substitution at position seven, where guanine is present in DCHBV instead of cytosine in HBV. Discussion This study presents the first confirmed occurrence of DCHBV in Serbia, expanding the known geographic distribution of this virus. Reported prevalence rates of DCHBV vary widely among studies conducted in different regions. In the present study, the prevalence of DCHBV in domestic cats was 2.6%, which is comparable to findings from Chile (1.67%) and Turkey (4%) (Adıgüzel et al. 2023; Choi et al. 2023). In contrast, markedly higher prevalence rates have been reported in Hong Kong, Thailand, and Italy, ranging from 10.8% to 17.6%, whereas lower rates (< 1%) were observed in Texas (USA), Germany, and Brazil (Lanave et al. 2019; Piewbang et al. 2020; Capozza et al. 2023a; Beatty et al. 2024; de Oliveira-Filho et al. 2025; Chen et al. 2025). Such discrepancies may be attributed to differences in sampling design, including sample types, diagnostic methods, and target populations. Importantly, the characteristics of the sampled population should be considered, as client-owned indoor cats are less likely to be exposed to infection compared to free-roaming or community cats (Beatty et al. 2024). No significant association was observed between DCHBV infection and coinfection status with FIV, FeLV, or FCoV. To date, only one study from Thailand has reported a positive association between DCHBV and FIV coinfection (Piewbang et al. 2020). Although molecular methods were used for viral detection in this study, this approach may not be optimal for identifying retroviral infections, which are more accurately diagnosed through serological testing. Future research investigating the association between coinfections should focus on antibody detection for more accurate results. Although seven of the eight DCHBV-positive animals were female, statistical analysis did not demonstrate a significant association with sex, likely due to the limited sample size. Our findings are consistent with previous observations indicating that neither sex nor age has a significant association with DCHBV infection (Lanave et al. 2019; Piewbang et al. 2020; Capozza et al. 2023a). However, larger numbers of DCHBV-positive animals are required to enable a more robust assessment of prevalence patterns across different population subgroups. Additionally, the reliance on convenience sampling may limit the extent to which the observed prevalence can be generalised to the broader domestic cat population. In this study, DCHBV DNA was detected in both blood and serum, providing insight into the viral pathogenesis and viraemia in cats. Recent research has demonstrated that DCHBV can establish persistent infection, with high initial viral DNA loads associated with prolonged viraemia (Wardhani et al. 2025). This supports the likelihood that DCHBV may circulate systemically for extended periods, contributing to long-term infection and potential disease development. Circulating viral DNA suggests active replication and systemic spread, and persistent DCHBV detection may therefore indicate ongoing viral replication and potential chronic infection. Similar patterns are well documented in HBV, where serum DNA levels help distinguish transient viraemia from chronic infection, and progressively decline with advancing hepatic fibrosis and cirrhosis (Liu et al. 2018). Phylogenetic analysis showed that the strains from Serbia belong to genotype A, which is globally distributed and currently the only genotype reported in Europe (de Oliveira-Filho et al. 2025). Currently, genotyping relies on ≥ 7.5% divergence across the full genome (de Oliveira-Filho et al. 2025). Notably, the Serbian strains did not cluster with those from neighbouring European countries but showed greatest similarity to strains from Taiwan (2023), France (2022) and the United Kingdom (2018). This pattern suggests that viral dissemination may be linked to the movement of companion animals or the international pet trade. Another likely explanation is the presence of unsampled intermediate lineages, which, together with the limited number of sequenced DCHBV genomes worldwide, contribute to the apparent phylogenetic randomisation and prevent a finer resolution of strain relationships. Despite this geographic separation, DCHBV exhibits a high degree of sequence conservation worldwide. Additional sequence data, particularly from regions that remain under-sampled, are needed to improve understanding of DCHBV phylogeography and transmission dynamics. Three amino acid substitutions in the S ORF were identified in the Serbian strains, two of which occurred at positions not previously reported in any other sequences. Comparative analysis showed that although the DCHBV_SRB_313_PX147449 sequence carried a unique substitution at position 204, other sequences also exhibited substitutions at this site. Strains from Brazil and Japan contained an I204T substitution, while strains from the USA and Chile carried an I204S substitution. DCHBV_SRB_313_PX147449 additionally exhibited an I274F substitution generated by two nucleotide changes (A355T and T357C). A comparable I274F substitution has been reported only once, in a sequence from Taiwan (PQ206355_Taiwan_2021), where it arose from a single-nucleotide mutation (A355T). In the phylogenetic analysis, the PQ206355_Taiwan_2021 sequence did not cluster with the Serbian sequences, indicating that the I274F substitution likely arose independently in both strains. The identified S ORF substitutions may increase the resolution of DCHBV molecular typing, and S ORF variability could support the development of refined sub-genotyping criteria that has been applied in HBV (Guirgis et al. 2010). Sequence analysis revealed a consistent 3-bp deletion in the PreS1 region that was present in all available DCHBV sequences except for the reference strain NC_040719. This finding suggests that the majority of circulating DCHBV strains naturally lack these three nucleotides, and that the reference sequence likely contains a 3-bp insertion within the PreS1 region. Nonsynonymous substitutions at positions 77, 89, and 99 were frequently observed, and DCHBV_SRB_313_PX147449 additionally harboured a unique substitution at position 70. In HBV, multiple mutations or deletions in the corresponding region have been associated with the development of HCC (Chuang et al. 2022). This observation may suggest a potential functional role for the high amino acid variability observed in this region of DCHBV. However, further investigation is needed to confirm any such relevance. The NTCP-binding domain of PreS1 plays a key role in mediating attachment to hepatocyte receptors. DCHBV PreS1 peptide can bind to human NTCP and vice versa, suggesting a conserved entry mechanism among hepadnaviruses (Shofa et al. 2023). High likelihood of N-terminal N-myristoylation in the DCHBV L protein is critical for NTCP receptor binding and efficient viral entry (Stone et al. 2022). These findings highlight that DCHBV utilises the same host cell entry pathway as HBV, reflecting the evolutionary conservation of key infection mechanisms among mammalian hepadnaviruses. In DCHBV, AT-rich sequences upstream of the preS1 region may serve a regulatory function and represent part of the putative preS1 promoter. However, unlike HBV, no canonical TATA box was identified in this region. The N-terminal precore region was highly conserved, with only minimal global variation. The N-terminal precore sequence of the precore protein functions as a signal peptide that directs the precursor protein (p25) into the endoplasmic reticulum, where a 10-amino-acid segment is cleaved by signal peptidase to produce the mature precore protein (p22). During the generation of mature HBeAg in the Golgi apparatus, a furin-like protease cleaves the p22 protein within the ARD (Prange 2022). The cysteine residue at position − 7 is essential for maintaining the dimeric state of the protein, whereas cysteines at positions − 16, −18, and − 23 are required for proper folding, processing, and transport of p25 (Zábranská et al. 2022). In this study, the N-terminal precore sequence of DCHBV was found to consist of 28 amino acids, compared to 29 in HBV. The DCHBV precore region contains conserved cysteine residues at positions − 7, −18, and − 22, the latter corresponding to position − 23 in HBV due to the one-amino-acid deletion. At the C-terminal end, the ARD region of DCHBV displays an overall structural similarity to that of HBV. The ARD functions as a nucleic acid chaperone, playing a role in capsid assembly and RNA encapsidation. This chaperone activity is dependent on the abundance of positively charged amino acids within the ARD and is known to be impaired by arginine-to-alanine substitutions (Chu et al. 2014). Although an alanine residue, which could potentially affect chaperone activity, was identified within the first arginine cluster of DCHBV, the presence of additional arginine residues in the ARD likely compensates by maintaining the overall positive charge of the region. In DCHBV, an AT-rich region was identified upstream of the C ORF and is proposed to represent the CP, including the BCP region. The CP plays a major regulatory role in the transcription of pcRNA and pgRNA in Hepadnaviruses. It consists of two functional regions: BCP and the upper regulatory region (URR). However, the BCP alone is sufficient to initiate transcription of both pcRNA and pgRNA (Quarleri 2014). The BCP lacks a canonical TATA box but contains several AT-rich sequences that serve as alternative promoter elements. In HBV, three TATA-like motifs (TA1, TA2, and TA3) have been identified as initiation sites for pcRNA transcription and can bind the TATA-binding protein, while a fourth motif (TA4) acts as an initiator element for both pcRNA and pgRNA transcription (Quarleri 2014). In DCHBV, we identified a motif comparable to the HBV TA4 region, the 5′-CATAAAAC-3′ sequence, which contains the 5′-CATA-3′ core motif corresponding to the initiator element of pcRNA (Quarleri 2014). In addition, the 5′-CATCT-3′ sequence was detected and could represent the equivalent of the HBV pgRNA Inr element (5′-CAACT-3′), suggesting a possible similar regulatory role in pgRNA transcription. This region may represent a regulatory element inolved intranscription of both pcRNA and pgRNA in DCHBV, although experimental validation is required. The putative BCP of DCHBV also contains the DR1 element, which is essential for reverse transcription in hepadnaviruses. DR1 and DR2 are crucial for maintaining genome circularity and play a central role in replication and reverse transcription of pgRNA (Quarleri 2014). It has been reported that most HBV integration breakpoints occur between DR2 and DR1, including within the CP region (Zhang et al. 2021). These regions represent major integration hotspots for the viral genome within the host genome, with integrations frequently occurring in or near DR1 and DR2 (Quarleri 2014). A recent study confirmed integration of the DCHBV genome into the host genome, with viral junction sites proposed to localise within the putative epsilon region near DR1. Integration events were detected near the promoter region of the feline CCNE1 homologue, a gene with a crucial role in cell cycle regulation and a recurrent integration site in HBV-associated HCC (Cavasin et al. 2025). These findings suggest that DR regions may contribute to viral genome integration, however, further investigation is required to clarify their exact role. DCHBV has been proposed as a surrogate model for HBV due to their notable genomic and functional similarities. However, our results suggest that the relevance of DCHBV may extend beyond comparative hepadnavirus research. In particular, the identification and characterisation of the ARD raise the possibility of additional biological roles which could be investigated in DCHBV, as ARD-derived peptides have been shown to possess broad-spectrum antimicrobial activity (Chen et al. 2013). This finding points to potential alternative applications of DCHBV-derived molecular components beyond viral pathogenesis alone. While HBV-based genome annotation provides a valuable framework for interpreting DCHBV genomic organisation and the proposed roles of the motifs, direct experimental validation remains essential to determine whether analogous regions in DCHBV fulfil equivalent biological functions. Molecular and protein analyses are fundamental for understanding DCHBV pathogenesis and its potential clinical consequences, particularly its proposed role in the development of HCC. Although accumulating evidence suggests that DCHBV may contribute to liver carcinogenesis in cats, substantial knowledge gaps remain regarding viral lifecycle dynamics, host immune responses, and the molecular mechanisms that may drive malignant transformation. Our findings highlight the importance of comprehensive molecular characterisation of DCHBV, which can serve as a foundation for future experimental studies that are necessary to confirm these potential roles. Continued genomic and functional studies will be essential to clarify the pathogenic capacity of DCHBV, its immunological and potential therapeutic relevance, and its value as a comparative model for HBV research. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5 Supplementary Material 6 Supplementary Material 6 Supplementary Material 7 Supplementary Material 7